Not investment advice. Educational platform. See Disclaimer.
NASDAQ: BIIB
Biogen Inc.
Healthcare | Drug Manufacturers - General
$216.12+22.38 (+11.55%)as of 2026-07-14 20:28 UTC
Market Cap$31.9B
Volume1.11M
EPS (TTM)$8.79
Biogen Inc. (NASDAQ: BIIB) is a $31.9B drug manufacturers - general company trading at $216.12 (+11.6% today) — 24.6× trailing earnings. Figures from SEC EDGAR and market feeds; updated 2026-07-14 20:28 UTC.
52-Week Range
Low $171.22High $219.00
What Biogen Inc. does
Biogen is a global biopharmaceutical company that discovers, develops and delivers medicines for serious and complex diseases, with particular focus on neurology, specialized immunology and rare diseases. The company markets multiple medicines for multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia and amyotrophic lateral sclerosis, and has collaborations on Alzheimer's disease and postpartum depression treatments.
Biogen is a global biopharmaceutical company that discovers, develops and delivers medicines for serious and complex diseases, with particular focus on neurology, specialized immunology and rare diseases.
What is BIIB's valuation?
BIIB trades at $216.12, 24.59× trailing earnings, as of 2026-07-14.
When did BIIB last file with the SEC?
Biogen Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-01. All filings link to their SEC EDGAR originals above.
Where does this data come from?
SEC EDGAR filings and public market data feeds, fetched 2026-07-14 20:28 UTC. This page is also available as JSON at /api/data?ticker=BIIB and is emitted with FAQPage structured data for machine reading.
For you
Charts, 10-year financials, peer comparison, screening and portfolio tracking for BIIB and 3,500+ tickers.
